2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. FOXO
  5. FOXO Isoform

FOXO

 

FOXO Related Products (8):

Cat. No. Product Name Effect Purity
  • HY-153347
    JY-2
    		99.75%
    JY-2 is a moderately selective and orally active Forkhead transcription factor forkhead box O1 (FoxO1) inhibitor that inhibits FoxO1 transcriptional activity with an IC50 of 22 μM. JY-2 shows moderate inhibition against FoxO3a and FoxO4. JY-2 shows anti-diabetic activity.
  • HY-15449
    Kaempferide
    		Agonist 99.80%
    Kaempferide is an orally active flavonol isolated from Hippophae rhamnoides L. Kaempferide has anticancer, anti-inflammatory, antioxidant, antidiabetic, antiobesity, antihypertensive, and neuroprotective activities. Kaempferide induces apoptosis. Kaempferide promotes osteogenesis through antioxidants and can be used in osteoporosis research.
  • HY-101035
    LOM612
    		98.85%
    LOM612 is a potent FOXO relocator, with an EC50 value of 1.5 μM in U2fox RELOC cells.
  • HY-153617
    FOXO1-IN-3
    		99.05%
    FOXO1-IN-3 is a highly-selective and orally active FOXO1 inhibitor. FOXO1-IN-3 reduces hepatic glucose production in mice. FOXO1-IN-3 improves insulin sensitivity and glucose control in db/db mice without causing weight gain.
  • HY-107566
    Conessine
    		Inhibitor 99.87%
    Conessine is an orally active and BBB-penetrable selective histamine H3 receptor antagonist. The pKi values of Conessine for rat and human H3 receptors are 7.61 and 8.27, respectively. Conessine is an inhibitor of the multidrug efflux pump system in Pseudomonas aeruginosa and can enhance the activity of antibiotics. Conessine has antimalarial activity. Conessine can also be used in the research of muscle atrophy.
  • HY-W072940
    Anticancer agent 7
    		Activator 99.26%
    Anticancer agent 7 (Example 5) modulates PP2A, and induces FOXOl transcription factor translocation to the nucleus. Anticancer agent 7 inhibits the proliferation of H1650 lung cancer cell with an IC50 of 5 μM.
  • HY-163982
    FOXJ1 agonist 1
    FOXJ1 agonist 1 (compound 16c) is an orally effective small molecule that can effectively enhance the expression of FOXJ1. Foxj1-IN-1 acts on the mammalian airway system composed of multiciliated cells (MCC) to prevent the development and onset of chronic obstructive pulmonary disease (COPD). Foxj1-IN-1 can induce the production of motile cilia in the respiratory system of zebrafish and mammals, and inhibit elastase-induced COPD mouse models. Foxj1-IN-1 has good liver microsomal stability, in vivo PK curve and AUC; it has no significant inhibition of CYP and hERG, and does not have significant cytotoxicity.
  • HY-107566A
    Conessine dihydrobromide
    		Inhibitor
    Conessine dihydrobromide is an orally active and BBB-penetrable selective histamine H3 receptor antagonist. The pKi values of Conessine dihydrobromide for rat and human H3 receptors are 7.61 and 8.27, respectively. Conessine dihydrobromide is an inhibitor of the multidrug efflux pump system in Pseudomonas aeruginosa and can enhance the activity of antibiotics. Conessine dihydrobromide has antimalarial activity. Conessine dihydrobromide can also be used in the research of muscle atrophy.